Nonetheless, the main perspective in clinical treatments for AATD is clearly the potentiation of autophagy, as Z-AAT accumulation activates a specific autophagic pathway capable of degrading insoluble forms of Z-AAT [252]. This evidence concerns the gene SERPINA1 and alpha 1-antitrypsin deficiency.